Mesoblast Ltd (NASDAQ:MESO)

6.29
Delayed Data
As of Oct 21
 +0.07 / +1.12%
Today’s Change
5.52
Today|||52-Week Range
17.41
-25.91%
Year-to-Date
SECTOR
Health Technology
INDUSTRY
Biotechnology
MARKET CAP
$736.9M

Company Description

Mesoblast Ltd. is a biopharmaceutical company, which engages in the research, development, and market of mesenchymal lineage adult stem cell technology platform. Its medicines target the cardiovascular diseases, spine orthopedic disorders, oncology and hematology, immune-mediated, and inflammatory diseases. The company was founded by Itescu Silviu on June 8, 2004 and is headquartered in Melbourne, Australia.

Contact Information

Mesoblast Ltd.
55 Collins Street
Melbourne Victoria (vic) 3000
P:(139) 639-6036
Investor Relations:

Employees

Shareholders

Other institutional1.70%
Mutual fund holders1.34%
Individual stakeholders--

Top Executives

Silviu ItescuChief Executive Officer, MD & Executive Director
Dagmar Rosa-BjorkesonChief Operating Officer
Andrew ChaponnelChief Financial Officer & Head-Finance
Fred GrossmanChief Medical Officer
Michael SchusterHead-Pharma Partnering